BOPI 07 BR/2023 REPERTOIRE NUMERIQUE 15 Fig. 1 Consulter le mémoire ________________________________________ (11) 21037 (51) A61K 47/68 (2018.01) (21) 1202100526 - PCT/US2020/033602 (22) 19/05/2020 (30) US n° 62/850,098 du 20/05/2019 (54) Mcl-1 inhibitor antibody-drug conjugates and methods of use. (72) GENESTE, Olivier (FR); KOTSCHY, Andras (HU); SIPOS, Szabolcs (HU); BURGER, Matthew, T. (US); CHANRION, Maia (FR); COLLAND, Frédéric (FR); CSEKEI, Marton (HU); DELACOUR, Lea (LU); DESOS, Patrice (FR); HENLIN, Jean-Michel (FR); KOSTOVA, Vesela (FR); MARAGNO, Ana, Leticia (FR); MCNEILL, Eric (US); PALERMO, Mark, G. (US); ROCCHETTI, Francesca (FR); STARCK, Jérôme (FR); YU, Bing (US); ZHANG, Qiang (US); CHEN, Zhuoliang (US); NAKAJIMA, Katsumasa (US); D'ALESSIO, Joseph, Anthony (US); BLANKENSHIP, John, William (US) et PROSZENYÁK, Ágnes (HU) (73) 1- Novartis AG, Lichtstrasse 35, 4056 BASEL (CH) et 2- Les Laboratoires Servier, 35 rue de Verdun, 92284 SURESNES Cedex (FR) (74) SPOOR & FISHER Inc. NGWAFOR & PARTNERS Sarl, The House of Gideon, Golf/Bastos Quarters, Opposite The American Embassy, Entrance-Saint John Paul II Boulevard, P.O. Box 8211, YAOUNDE (CM). (57) Anti-CD74 antibody-drug conjugates are disclosed. The anti-CD74 antibody-drug conjugates comprise an Mcl-1 inhibitor dnig moiety and an anti-CD74 antibody or antigenbinding fragment thereof that binds an antigen target, e.g.. an antigen expressed on a tumor or other cancer cell. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linkerdrug conjugates comprising an Mcl-1 inhibitor drug moiety and methods of making same arc also disclosed. Formula (I) Consulter le mémoire
RkJQdWJsaXNoZXIy MTM1NDc3MA==